Adma Biologics, Inc.

Morgan, Consisting of a $75 Million Term Loan Drawn at Closing to Replace Existing Debt and a $225 Million Unused Revolving Credit Facility; Significantly Lowers Borrowing Costs and Enhances Strategic Optionality Expanded Production Operations Infrastructure with the Acquisition of a New Boca Raton Operating Site to Strengthen Vertically Integrated U.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Grossman concluded, In parallel, and following completion of the second quarter, we further optimized our capital structure through a syndicated debt refinancing led by J.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Morgan, which should meaningfully reduce our borrowing costs while enhancing liquidity and strategic optionality through a new $225 million revolving credit facility.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Supported by these strategic achievements, ADMA repurchased approximately $15 million of common stock during the second quarter demonstrating conviction in the Company s long-term value creation potential.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

ADMA anticipates modest capital expenditure requirements to support the expansion and ultimately expects to realize a compelling Return on Investment (ROI) from enhanced operations and potential capacity expansion.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Approximately $15 Million in Common Stock Repurchased Under Share Buyback Program.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Morgan, Consisting of a $75 Million Term Loan Drawn at Closing to Replace Existing Debt and a $225 Million Unused Revolving Credit Facility; Significantly Lowers Borrowing Costs and Enhances Strategic Optionality Expanded Production Operations Infrastructure with the Acquisition of a New Boca Raton Operating Site to Strengthen Vertically Integrated U.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The successful initiation of yield-enhanced manufacturing marks a key inflection point driving expected gross margin expansion, reinforcing ADMA s forecasted growth trajectory, and positioning the Company for an accelerating pace of revenue and earnings growth in the periods ahead.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Morgan, which should meaningfully reduce our borrowing costs while enhancing liquidity and strategic optionality through a new $225 million revolving credit facility.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Combined with anticipated strong cash generation, this enhanced financial flexibility supports our ability to invest in growth, advance our supply chain initiatives, and deliver sustainable long-term value.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

-based supply chain with an infrastructure expansion by acquiring a facility and land adjacent to our Boca Raton campus, which we believe will create operational efficiencies and ultimately support up to a 30% increase in cGMP manufacturing footprint.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

-based, end-to-end operations should substantially insulate the Company from global trade disruptions and tariffs while enhancing supply chain resilience and regulatory compliance.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

In initial pilot testing, SG-001-treated animals exhibited no clinical signs of pneumonia 24 hours post-bacterial challenge, while placebo-treated animals developed observable symptoms.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Morgan and benefits thereof; the Company s insulation from global trade disruptions and tariffs and supply chain stability ; our newly acquired site in Boca Raton, FL, potential expansion of cGMP manufacturing space as a result of such expansion, potential efficiencies and operating flexibility and other benefits from such site, and required capital expenditure requirements; ASCENIV s market penetration and new patient growth; and statements regarding SG-001 and its development and revenue potential.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks and uncertainties described in our filings with the SEC, including our most recent reports on Form 10-K, 10-Q and 8-K, and any amendments thereto.

SEC original ↗Adma Biologics, Inc. — Earnings release (8-K exhibit)EX-99Aug 6, 2025

i Index Special Note Regarding Forward-Looking Statements This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act ), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act ), and such forward-looking statements involve risks and uncertainties.

SEC original ↗Adma Biologics, Inc. — 10-Q Quarterly report10-QAug 5, 2026

tariff policies and any anticipated effects of such factors on the pricing and availability of imported raw materials used in the production of our products.

SEC original ↗Adma Biologics, Inc. — 10-Q Quarterly report10-QAug 5, 2026